Company news
Assertio Holdings, Inc. news in 2026
Assertio Holdings, Inc.'s news releases, calls and decks from 2026, newest first.
Astellas to Spotlight New Research for Geographic Atrophy at ASRS 2026 Annual Meeting
July 9, 2026
Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027
June 16, 2026
Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash
May 13, 2026
Assertio and Garda Mutually Agree to Delay Launch of Tender Offer
May 8, 2026
Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer
May 5, 2026
Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics
May 4, 2026
Assertio and Garda Mutually Agree to Extend Tender Offer Deadline
April 29, 2026
Assertio Provides Update on Garda Therapeutics Tender Process
April 21, 2026
Assertio Announces Agreement to be Acquired by Garda Therapeutics
April 7, 2026
Assertio Reports Fourth Quarter and Full Year 2025 Financial Results
March 16, 2026
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
March 3, 2026
Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements
January 12, 2026
Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial
January 9, 2026